This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Booster Dose Gets CDC Backing for Older Adults Only
by Zacks Equity Research
The CDC recommends Pfizer (PFE)/ BioNTech's (BNTX) COVID-19 vaccine booster shots for older adults only but not for high-risk workers.
Pharma Stock Roundup: PFE Booster Jab Gets FDA Nod, JNJ's New Data on COVID-19 Shot
by Kinjel Shah
FDA grants EUA to Pfizer (PFE)/BioNTech's COVID-19 vaccine booster shots for limited use. J&J (JNJ) announces phase III data on booster dose of its single-shot vaccine.
Nike, Costco Report Better Earnings than Expected
by Mark Vickery
Both Nike and Costco beat bottom-line estimates in their subsequent quarters, but struggled to match on the top-line.
Will Pfizer ETFs Soar on FDA's COVID-19 Vaccine Booster Approval?
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in coronavirus vaccine.
Pfizer (PFE) Booster Dose Gets FDA Nod for High-Risk People
by Zacks Equity Research
FDA approves Pfizer's (PFE) COVID-19 vaccine booster shots for older adults and high-risk people amid rising infection rates in the country.
BioNTech SE Sponsored ADR (BNTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $339.26, marking a -0.61% move from the previous day.
J&J's (JNJ) New Data Shows COVID-19 Booster Ups Protection
by Zacks Equity Research
J&J's (JNJ) data showed that a booster dose of its vaccine generated 94% efficacy against mild-to-severe COVID-19 in the United States. The data also confirmed that even one dose offers strong and long-lasting protection.
Pfizer's (PFE) COVID-19 Vaccine Successful in Children Study
by Zacks Equity Research
Pfizer (PFE) and BioNTech's Comirnaty generates non-inferior immune response in children aged 5 to 11 years in pivotal pediatric study compared to the immune response in adults.
Company News for Sep 21, 2021
by Zacks Equity Research
Companies In The News Are: TSLA, AAL, PFE, BNTX, F.
September Syndrome Deepens in Markets
by Zacks Equity Research
September Syndrome Deepens in Markets.
Contagion Fears Squeeze Pre-Market Futures
by Mark Vickery
It's difficult to know what's going on in the minds of the Chinese market authorities, but for those great American companies less reliant on the Chinese economy, it may be a good time to bring out our wish-list.
FDA Panel Vetoes PFE/BNTX Third Jab for All, Vaccine Stocks Down
by Kinjel Shah
Pfizer (PFE) and Moderna (MRNA) are the only two companies that have submitted data and are seeking approval for a booster or "third" dose of their COVID-19 vaccines.
Pfizer, Moderna Support COVID Vaccine Booster Before FDA Meet
by Zacks Equity Research
Amid rising coronavirus cases, PFE and MRNA are trying to make booster doses of their COVID-19 vaccine available for US citizens. An FDA meeting is scheduled tomorrow to discuss Comirnaty's booster dose.
Markets Melt Down on Profit Taking, Not Economic Logic: 5 Picks
by Nalak Das
We have narrow down the search to five stocks that have provided double-digit returns year to date. These are: HPQ, LKQ, KSS, M and X.
5 Top-Ranked Large-Cap Stocks That Have Skyrocketed YTD
by Nalak Das
We have narrowed down our search to five large-cap stocks with strong potential for the rest of 2021. These are: NUE, ON, KMX, ORLY and ULTA.
Will COVID-19 Vaccines for Children be Available by Year-End?
by Zacks Equity Research
The FDA is trying to make available a safe and effective COVID-19 vaccine for use in children below 12 years of age as soon as possible.
Why U.S. Airline Stocks Gained Yesterday Despite Dim Views
by Maharathi Basu
Stocks like Delta (DAL), American Airlines (AAL) and Southwest (LUV) gain on Thursday despite the Delta variant-induced dull warnings.
Moderna (MRNA) Inks Deal to Develop Ultra-Rare Disease Therapy
by Zacks Equity Research
Moderna (MRNA) inks a collaboration deal with the Institute for Life Changing Medicines to develop a free of charge mRNA-based therapy to treat Crigler-Najjar Syndrome type 1, an ultra-rare disease.
Moderna (MRNA) Seeks Authorization for Booster Dose in Europe
by Zacks Equity Research
Moderna (MRNA) is developing a booster dose of its COVID-19 vaccine, mRNA-1273, for enhancing protection against infection in individuals.
Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies
by Zacks Equity Research
Celsion (CLSN) announces data from pre-clinical studies for its investigational vaccine platform as a potential treatment for COVID-19.
Moderna (MRNA) Gives First COVID Jab Booster Data to the FDA
by Zacks Equity Research
Moderna's (MRNA) booster dose of COVID-19 vaccine elicits antibody levels that were much higher than that seen after the two-dose primary schedule.
5 Top Picks to Boost Portfolio in Historically Weak September
by Nalak Das
We have narrowed down our search to five stocks that have provided more than 20% returns year to date. These are: DKS, KSS, ANF, RCII and HPQ.
Moderna (MRNA) Japan Jabs Resume Amid Safety Risk Per Reports
by Zacks Equity Research
Japan allows use of uncontaminated vials from the same lots of Moderna's (MRNA) COVID-19 vaccine that had some contaminated vials, which led to the temporary halt of vaccination in some parts of the country.
DAL Ups Unvaccinated Health Costs: Other Airlines to Follow?
by Maharathi Basu
Delta Air's (DAL) decision is aimed at addressing the financial perils the company might grapple with pertaining to unvaccinated employees.
Sorrento's (SRNE) COVID Vaccine Effective in Pre-Clinical Study
by Zacks Equity Research
Sorrento (SRNE) announces data from pre-clinical study for its investigational mRNA COVID vaccine. The company also in-licensed rights to highly potent main protease inhibitors against COVID variants.